TY - JOUR
T1 - Models of melanoma metastasis
T2 - using a transient siRNA-based protein inhibition strategy in mice to validate the functional relevance of pharmacological agents.
AU - Sharma, Arati
AU - Robertson, Gavin
PY - 2007/1/1
Y1 - 2007/1/1
N2 - While a pharmacological agent may inhibit the activity of a protein in cultured cells by triggering a particular biological process, it may function differently in intact animals. Thus, an assay is needed to rapidly assess whether a drug candidate displays the same mechanism of action in vivo as in vitro. The experimental approach described in this unit utilizes synthetic siRNA in a transient animal assay to define the action of a drug candidate when inhibiting the activity of a particular gene. Commercially available synthetic siRNA is introduced into cancer cells by nucleofection to reduce protein expression. Cells are then introduced into animals and the mechanism responsible for tumor inhibition assessed. The action of a compound identified in vitro is then compared to that noted in vivo following siRNA-mediated inhibition to determine whether it reduces tumor development in the same manner in both systems.
AB - While a pharmacological agent may inhibit the activity of a protein in cultured cells by triggering a particular biological process, it may function differently in intact animals. Thus, an assay is needed to rapidly assess whether a drug candidate displays the same mechanism of action in vivo as in vitro. The experimental approach described in this unit utilizes synthetic siRNA in a transient animal assay to define the action of a drug candidate when inhibiting the activity of a particular gene. Commercially available synthetic siRNA is introduced into cancer cells by nucleofection to reduce protein expression. Cells are then introduced into animals and the mechanism responsible for tumor inhibition assessed. The action of a compound identified in vitro is then compared to that noted in vivo following siRNA-mediated inhibition to determine whether it reduces tumor development in the same manner in both systems.
UR - http://www.scopus.com/inward/record.url?scp=84873266558&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84873266558&partnerID=8YFLogxK
M3 - Article
C2 - 21948165
AN - SCOPUS:84873266558
SN - 1934-8282
VL - Chapter 14
JO - Current protocols in pharmacology / editorial board, S.J. Enna (editor-in-chief) ... [et al.]
JF - Current protocols in pharmacology / editorial board, S.J. Enna (editor-in-chief) ... [et al.]
ER -